Varsha Gandhi

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

69h-index19.4kcitations694works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(324), Acute Lymphoblastic Leukemia research(128), Lymphoma Diagnosis and Treatment(106), Acute Myeloid Leukemia Research(80), Biochemical and Molecular Research(79)

Publications693 total

Supplementary Tables S1-S3 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
2025Open Access
Supplementary Methods S1 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
2025Open Access
Supplementary Figures S1-S4 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
2025Open Access
Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial
Blood·2025
Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study
Blood·2025Open Access
Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia
Blood·2025· 1 citedOpen Access
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression
Blood Cancer Journal·2025Open Access
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia
Blood·2025· 1 citedOpen Access
Figure S2 from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025Open Access
Figure S3 from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025Open Access
Table S1 from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025Open Access
Figure S1 from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025Open Access
Data from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025Open Access
Figure S4 from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025Open Access
Supplementary Materials and Methods from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025Open Access
Table S2 from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025Open Access
Inhibition of de novo Lipogenesis through Acly and FASN Sensitizes PDAC to RT and Ferroptosis
International Journal of Radiation Oncology*Biology*Physics·2025
Quercetin, A Natural Flavonoid Compound, and Pancreatic Ductal Adenocarcinoma to Radiation Therapy
International Journal of Radiation Oncology*Biology*Physics·2025
Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
Molecular Cancer Therapeutics·2025· 2 citedOpen Access
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression
2025· 2 citedOpen Access
page 1 of 35Next →

Frequent Co-authors

William Plunkett(24), Michael J. Keating(18), William G. Wierda(15), Kumudha Balakrishnan(10), Jan A. Burger(7), Hagop M. Kantarjian(7), Jörge E. Cortes(6), Peng Huang(4), Zeev Estrov(4), Prithviraj Bose(4), Elihu H. Estey(4), Rong Chen(4), Min Du(4), Lisa S. Chen(4), Mary Ayres(4), Nitin Jain(3), Philip A. Thompson(3), Alessandra Ferrajoli(3), Marina Konopleva(3), Nichole Cruz(3)